Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Up 5.22%
As of Friday, October 09, MAIA Biotechnology, Inc.’s MAIA share price has surged by 5.22%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Commentary & Analysis
Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Up 6.54%
As of Monday, September 14, MAIA Biotechnology, Inc.’s MAIA share price has surged by 6.54%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Up 11.12%
As of Wednesday, September 02, MAIA Biotechnology, Inc.’s MAIA share price has surged by 11.12%, which has investors questioning if this is right time to sell.Michael Rose
Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Up 6.66%
As of Tuesday, August 25, MAIA Biotechnology, Inc.’s MAIA share price has surged by 6.66%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why MAIA Biotechnology, Inc.’s (MAIA) Stock Is Up 5.08%
As of Tuesday, July 21, MAIA Biotechnology, Inc.’s MAIA share price has surged by 5.08%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | MAIA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $66.9 | $208.8 | 19% |
|
| Shares Out (Mil) | 60.8 | 53.9 | 52% |
|
| Institutional Ownership | 74.9% | 93.1% | 45% |
|
| Float (Mil) | 55.3 | 41.4 | 49% |
|
| Beta | 0.25 | 0.95 | 15% |
|
| Avg Daily Volume (000s) | 397 | 614 | 54% |
|
| Price Change (52-week) |
(23.6%) | 45.3% | 34% |
|
| Growth | MAIA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (27.7%) | (10.2%) | 15% |
|
| EPS (5yr) | 14.2% | 15.7% | 55 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 34.0% | (15.7%) | 88% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($0.130) | ($0.540) | $1.110 | |
| Month Ago EPS | ($0.130) | ($0.540) | $1.110 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.120) | ($0.520) | $1.120 | |
| Year/Year Chg | (0.8%) | (22.5%) | na | |
| Financials | MAIA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($27) | ($44) | 22% |
|
| EPS (TTM) | ($0.608) | ($1.600) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | ($33) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $56 | $174 | 17% |
|
| Valuation | MAIA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.24 | 2.09 | 70% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MAIA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (136.7%) | (47.2%) | 4% |
|
| ROE | (218.7%) | (54.2%) | 4% |
|
| Liabilities to Assets | 26.8% | 29.1% | 18% |
|
| F-Score | 3 | 2 | 18% |
|
MAIA Biotechnology, Inc. did not pass any screens on 10/16/2026.
